Healthcare Industry News: human growth hormone
News Release - February 20, 2008
Cook Pharmica Names Fred Larimore, Ph.D., Vice President of Scientific Affairs, CSO
25-Year Industry Veteran Announced as Newest Vice President of Cook Medical's Global Contract Biopharmaceutical Manufacturing OrganizationBLOOMINGTON, Ind.--(HSMN NewsFeed)--Fred Larimore, Ph.D. has been named vice president of scientific affairs and chief scientific officer for Cook Pharmica, the global contract biopharmaceutical manufacturing division of Cook Medical.
Larimore has more than 25 years of biotech experience beginning at Eli Lilly with the development and manufacturing of recombinant human insulin. His career at Eli Lilly included integral work for recombinant human growth hormone, recombinant human parathyroid hormone, bovine somatotropin, and several research monoclonal antibodies and antibody conjugates. Additionally, he led multiple initiatives in process aspects of facility design, scale-up and start-up.
As one of the top scientists at Eli Lilly, he was responsible for the redevelopment of the recombinant human insulin and recombinant human growth hormone processes and provided technical leadership and oversight for the company’s protein product portfolio prior to joining Cook Pharmica in 2006.
“Fred has provided critical leadership for the development group for the last two years and has been extremely effective in building a strong team,” said Cook Pharmica president Jerry Arthur. “His extensive industry experience, scientific expertise, and strong leadership qualities have been foundational to the success of our company and will continue to be as we expand.”
About COOK Pharmica:
Cook Pharmica (www.cookpharmica.com) is a contract biopharmaceutical manufacturing organization manufacturing mammalian cell culture-based pharmaceuticals for pre-clinical through commercial use. Cook Pharmica also offers cell line/strain development, clone selection, cell line adaptation, media optimization, process development, analytical development, cell banking/storage, stability testing/storage and regulatory submission support, and will be offering parenteral contract filling and finishing in early 2010.
About Cook Medical
Cook Medical, one of the world’s largest privately held medical device company with 15 manufacturing facilities and more than 7,000 employees worldwide, has pioneered countless innovative minimally invasive interventional technologies for diagnostic and therapeutic procedures and is leading the way in the convergence of devices, drug-eluting coatings, bio-derived materials, and cell and gene therapies that will further benefit patients in the 21st Century. One of the fastest-growing medical technology companies in the world since its founding in 1963, Cook is recognized as a leading developer, manufacturer and global distributor of cutting-edge interventional therapies in the fields of radiology, cardiology, urology, aortic intervention, peripheral intervention including peripheral vascular, bone access and oncology, women’s health and other gender-specific procedures, critical care medicine, surgery and soft tissue repair, gastroenterology and cellular and genetic therapies in addition to contract manufacturing. With global headquarters in Bloomington, Ind., the company won the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. For more information, visit www.cookmedical.com.
Source: Cook Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
